Striz I, Zheng L, Wang Y M, Pokorná H, Bauer P C, Costabel U
Immunology Unit, Institute of Chest Diseases, Prague, Czech Republic.
Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):544-7. doi: 10.1164/ajrccm.151.2.7531099.
CD14 is a myeloid differentiation antigen which exists in a membrane-bound (55 kD) and a soluble (48 kD) form. This antigen is a receptor for lipopolysaccharide (LPS) structures and triggers the production of various cytokines. The aim of this study was to evaluate whether in active sarcoidosis, a disease with increased proportions of alveolar macrophages (AM) with CD14 expression in BAL fluid, the soluble form of CD14 (sCD14) is also increased. The sCD14 levels were measured in BAL fluid with an ELISA, and membrane-bound CD14 was determined by an immunoperoxidase assay, in active sarcoidosis (n = 13), inactive sarcoidosis (n = 9), idiopathic pulmonary fibrosis (IPF) (n = 6), and control subjects (n = 8). Higher concentrations of sCD14 were present in BAL fluid of patients with active sarcoidosis (58 +/- 34 ng/ml) than in those with inactive disease (13 +/- 10 ng/ml), patients with IPF (5 +/- 5 ng/ml), or control subjects (10 +/- 8% ng/ml) (p < 0.01). Similarly, the proportions of AM expressing membrane-bound CD14 were increased in active sarcoidosis (91 +/- 6%) compared with inactive sarcoidosis (82 +/- 6%), patients with IPF (76 +/- 13%), and control subjects (79 +/- 9%) (p < .05). In sarcoidosis, a significant correlation was found between the sCD14 concentration in BAL fluid and AM membrane expression of CD14 (r = 0.57, p < 0.01). We conclude that sCD14 is increased in BAL of active sarcoidosis suggesting a potential role for this substance as marker of activity and in the pathogenesis of pulmonary sarcoidosis.
CD14是一种髓系分化抗原,以膜结合形式(55kD)和可溶性形式(48kD)存在。该抗原是脂多糖(LPS)结构的受体,可触发多种细胞因子的产生。本研究的目的是评估在结节病活动期(一种肺泡巨噬细胞(AM)在支气管肺泡灌洗(BAL)液中CD14表达比例增加的疾病)中,可溶性CD14(sCD14)是否也增加。采用酶联免疫吸附测定(ELISA)法检测BAL液中的sCD14水平,并用免疫过氧化物酶测定法测定膜结合CD14,研究对象包括结节病活动期患者(n = 13)、结节病非活动期患者(n = 9)、特发性肺纤维化(IPF)患者(n = 6)和对照组(n = 8)。结节病活动期患者BAL液中的sCD14浓度(58±34 ng/ml)高于结节病非活动期患者(13±10 ng/ml)、IPF患者(5±5 ng/ml)或对照组(10±8 ng/ml)(p<0.01)。同样,与结节病非活动期患者(82±6%)、IPF患者(76±13%)和对照组(79±9%)相比,结节病活动期表达膜结合CD14的AM比例增加(91±6%)(p< .05)。在结节病中,BAL液中的sCD14浓度与AM膜上CD14的表达之间存在显著相关性(r = 0.57,p<0.01)。我们得出结论,结节病活动期BAL中的sCD14增加,提示该物质作为活动标志物以及在肺结节病发病机制中可能发挥作用。